BMRN
NasdaqBioMarin Pharmaceutical Inc
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$1.8B
2021
$2.1B
2022
$2.4B
2023
$2.9B
2024
$3.2B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$3.2B
Net Income$348.9M
Gross Profit—
Oper Income$409.5M
EPS (dil)$1.80
Rev/sh$16.67
FCF/sh$3.75
Book/sh$31.49
Gross M—
Oper M12.7%
Profit M10.8%
FCF M22.5%
ROE5.7%
ROA4.6%
ROIC5.5%
R&D/Rev28.6%
Rev Y/Y12.9%
Rev 3Y CAGR15.4%
EPS Y/Y-18.6%
EPS 3Y CAGR33.9%
FCF 3Y CAGR136.3%
Payout—
Div/sh—
Shs Chg Y/Y+0.3%
Current Ratio5.21
Quick Ratio3.50
Debt/Eq0.10
Int Coverage37.6×
Net Debt$714.5M cash
Total Debt$597.2M
Cash & Eq$1.3B
Total Assets$7.6B
Oper CF$828.0M
Capex$103.0M
Free CF$725.0M
Buybacks$0
Equity$6.1B
Liabilities$1.5B
Shs Outstand0.19B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.8B | $2.1B | $2.4B | $2.9B | $3.2B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-82.3M | $161.0M | $185.8M | $484.2M | $409.5M |
| Net Income | $-64.1M | $141.6M | $167.6M | $426.9M | $348.9M |
| Diluted EPS | $-0.35 | $0.75 | $0.87 | $2.21 | $1.80 |
| Operating Cash Flow | $304.5M | $175.9M | $159.3M | $572.8M | $828.0M |
| Free Cash Flow | $209.0M | $54.9M | $62.6M | $487.4M | $725.0M |
COMMUNITY · $BMRN0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.